Department of Cardiothoracic Surgery, University of Louisville and Norton Children's Hospital, Louisville, Kentucky.
Department of Cardiothoracic Surgery, University of Louisville and Norton Children's Hospital, Louisville, Kentucky.
Ann Thorac Surg. 2024 Jan;117(1):136-142. doi: 10.1016/j.athoracsur.2023.01.003. Epub 2023 Jan 10.
We evaluated the impact of significant renal dysfunction (SRD) on listing and pediatric heart transplantation (PHT) outcomes.
The United Network of Organ Sharing registry was queried. Our cohort included 11,625 children listed for PHT (2000-2020). At listing, 1494 (13%) had SRD, defined as an estimated glomerular filtration rate of <45 mL/min/1.73 m and/or dialysis requirement. Characteristics of children with and without SRD were compared. SRD impact on outcomes was examined. Factors associated with waiting list mortality, persistent SRD at PHT, and post-PHT survival with and without simultaneous heart-kidney transplantation were assessed.
Compared with children with an estimated glomerular filtration rate >45 mL/min/1.73 m, those with SRD had higher waiting list death (37% vs 14%, P < .01) and lower transplantation rate (51% vs 71%, P < .01). On multivariable analysis, SRD was associated with waiting list death (hazard ratio, 3.016; P < .0001). Among 767 children with SRD who received PHT, 361 (47%) had persistent SRD at the time of PHT. On multivariable analysis, factors associated with persistent SRD were older age (odds ratio [OR], 1.147 per year; 95% CI, 1.046-1.258 per year; P = .0035), bilirubin (OR, 1.127 per 1-mg/dL; 95% CI, 1.061-1.197 per 1-mg/dL; P < .0001), dialysis (OR, 1.839; 95% CI, 1.017-3.326; P = .0115), mechanical ventilation (OR, 1.972; 95% CI, 1.336-2.911; P = .0006), extracorporeal membrane oxygenation (OR, 1.747; 95% CI, 1.074-2.842; P = .0247), and not using a ventricular assist device (VAD) (OR, 0.498 [VAD use]; 95% CI, 0.277-0.895 VAD use; P = .0198). Post-PHT survival was 72%, 70%, and 56% (P < .01) at 8 years for PHT alone with improved renal function, simultaneous heart-kidney transplantation (n = 69), and PHT alone with persistent SRD, respectively.
SRD is associated with high waiting list death and decreased transplantation rate. Timely proper pre-PHT support with VAD could enhance kidney recovery. Simultaneous heart-kidney transplantation neutralized persistent SRD effect on survival and might be considered in high-risk patients such as those on dialysis, mechanical ventilation, or extracorporeal membrane oxygenation support.
我们评估了严重肾功能障碍(SRD)对患儿心脏移植(PHT)名单和结局的影响。
我们查询了器官共享联合网络登记处。我们的队列包括 11625 名接受 PHT (2000-2020 年)的儿童。在列入名单时,1494 名(13%)患有 SRD,定义为估算肾小球滤过率<45ml/min/1.73m 和/或透析需求。比较了有和没有 SRD 的患儿的特征。检查了 SRD 对结局的影响。评估了与等待名单死亡率、PHT 时持续 SRD 以及同时进行心脏-肾脏移植时和不进行同时心脏-肾脏移植时的 PHT 后生存率相关的因素。
与估算肾小球滤过率>45ml/min/1.73m 的患儿相比,有 SRD 的患儿等待名单死亡率更高(37%比 14%,P<0.01),移植率更低(51%比 71%,P<0.01)。多变量分析显示,SRD 与等待名单死亡相关(危险比,3.016;P<0.0001)。在 767 名患有 SRD 并接受 PHT 的患儿中,361 名(47%)在 PHT 时仍有持续的 SRD。多变量分析显示,持续 SRD 的相关因素为年龄较大(优势比,每年增加 1.147;95%可信区间,每年增加 1.046-1.258;P=0.0035)、胆红素(优势比,每增加 1mg/dL 增加 1.127;95%可信区间,每增加 1mg/dL 增加 1.061-1.197;P<0.0001)、透析(优势比,1.839;95%可信区间,1.017-3.326;P=0.0115)、机械通气(优势比,1.972;95%可信区间,1.336-2.911;P=0.0006)、体外膜氧合(优势比,1.747;95%可信区间,1.074-2.842;P=0.0247)和未使用心室辅助装置(VAD)(优势比,0.498[使用 VAD];95%可信区间,0.277-0.895 使用 VAD;P=0.0198)。单独 PHT 的 8 年生存率分别为 72%、70%和 56%(P<0.01),肾功能改善、同时进行心脏-肾脏移植(n=69)和单独 PHT 时持续 SRD 分别为 72%、70%和 56%。
SRD 与高等待名单死亡率和低移植率相关。在 PHT 前及时适当使用 VAD 进行支持,可以促进肾脏恢复。同时进行心脏-肾脏移植可以中和持续 SRD 对生存率的影响,对于透析、机械通气或体外膜氧合支持等高危患者,可能需要考虑同时进行心脏-肾脏移植。